JTCR 016

Drug Profile

JTCR 016

Alternative Names: High-affinity WT1-specific TCR T cells - Juno Therapeutics; HLA-A2/WT1-specific TCR T cells - Juno Therapeutics; JTCR016; WT1 TCR-transduced T-cell therapy - Juno Therapeutics; WT1-sensitised T cells - Juno Therapeutics

Latest Information Update: 09 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Juno Therapeutics
  • Developer Fred Hutchinson Cancer Research Center; Juno Therapeutics
  • Class Cancer vaccines; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Gene transference; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Chronic myeloid leukaemia; Mesothelioma; Myelodysplastic syndromes; Non-small cell lung cancer; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 06 Mar 2018 Juno Therapeutics has been acquired by Celgene Corporation
  • 22 Mar 2017 Juno Therapeutics plans a third phase I/II trial for Acute myeloid leukaemia in USA
  • 20 Apr 2016 Positive initial efficacy and adverse events data from a phase I/II trial in Non-small cell lung cancer and Mesothelioma released by Juno Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top